Azithromycin to reduce childhood mortality in Sub-Saharan Africa
This study hypothesized that mass distribution of a broad-spectrum antibiotic agent to preschool children would reduce mortality in areas of sub-Saharan Africa
MDA
The effect of antibiotic selection pressure on the nasopharyngeal macrolide resistome: a cluster-randomized trial
This study compares two different frequencies of mass azithromycin distributions for trachoma to determine the causal relationship between antibiotic consumption and antibiotic resistance.
Coverage, social mobilization and challenges of mass Zithromax administration
This study assesses mass Zithromax administration coverage, social mobilization and campaign challenges in south and southeast zones of Tigray, Ethiopia.
Population-based coverage survey results following the mass drug administration of azithromycin for the treatment of trachoma in Amhara, Ethiopia
This coverage survey was conducted as part of an ongoing monitoring strategy within the Amhara Trachoma Control Program. The Carter Center provided the Amhara Regional Health Bureau with support to implement MDA, and separately, also funded, designed and executed this survey in collaboration with the Regional Health Bureau.
Prevalence of trachoma in the Kayes region of Mali eight years after stopping mass drug administration
The impact of a single round of community mass treatment with azithromycin on disease severity and ocular Chlamydia trachomatis load in treatment-naïve trachoma-endemic island communities in West Africa
Prevalence of Chlamydia trachomatis-specific antibodies before and after mass drug administration for trachoma in community-wide surveys of four communities in Nepal
Data from this study suggests that antibody responses could be useful indicators for post-validation surveillance.
Reaching remote Amazonian communities to eliminate trachoma
Originally posted in Community Eye Health Journal Vol.30 No.99.
Effectiveness of expanding annual mass azithromycin distribution treatment coverage for trachoma in Niger: a cluster randomised trial
The WHO recommends 3–5 years of annual mass azithromycin distribution with at least 80% treatment coverage to districts with active trachoma prevalence over 10% among children. This article assesses the efficacy of expanding the coverage target to at least 90% for trachoma control in a mesoendemic region of Niger.
Treating village newcomers and travellers for trachoma: Results from ASANTE cluster randomized trial
This trial was designed to determine if a surveillance program that targeted newcomers and travellers would result in more communities achieving levels of infection of ≤1%.
